Your browser doesn't support javascript.
loading
An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia.
Ng, Kevin; Titus, Erron W; Lieve, Krystien V; Roston, Thomas M; Mazzanti, Andrea; Deiter, Frederick H; Denjoy, Isabelle; Ingles, Jodie; Till, Jan; Robyns, Tomas; Connors, Sean P; Steinberg, Christian; Abrams, Dominic J; Pang, Benjamin; Scheinman, Melvin M; Bos, J Martijn; Duffett, Stephen A; van der Werf, Christian; Maltret, Alice; Green, Martin S; Rutberg, Julie; Balaji, Seshadri; Cadrin-Tourigny, Julia; Orland, Kate M; Knight, Linda M; Brateng, Caitlin; Wu, Jeremy; Tang, Anthony S; Skanes, Allan C; Manlucu, Jaimie; Healey, Jeff S; January, Craig T; Krahn, Andrew D; Collins, Kathryn K; Maginot, Kathleen R; Fischbach, Peter; Etheridge, Susan P; Eckhardt, Lee L; Hamilton, Robert M; Ackerman, Michael J; Noguer, Ferran Rosés I; Semsarian, Christopher; Jura, Natalia; Leenhardt, Antoine; Gollob, Michael H; Priori, Silvia G; Sanatani, Shubhayan; Wilde, Arthur A M; Deo, Rahul C; Roberts, Jason D.
  • Ng K; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Western University, London, ON, Canada (K.N., J.W., A.S.T., A.C.S., J.M., J.D.R.).
  • Titus EW; Cairns Hospital, Queensland, Australia (K.N.).
  • Lieve KV; Cardiovascular Research Institute (E.W.T., F.H.D., N.J.R., R.C.D.), University of California, San Francisco.
  • Roston TM; Amsterdam University Medical Centre, University of Amsterdam, Heart Centre, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, The Netherlands (K.V.L., C.v.d.W., A.A.M.W.).
  • Mazzanti A; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (K.V.L., A. Mazzanti, I.D., T.R., C.v.d.W., A. Maltret, A.L., A.A.M.W., S.G.P.).
  • Deiter FH; Heart Rhythm Services, Division of Cardiology, Department of Medicine (T.M.R., A.D.K.), University of British Columbia, Vancouver, Canada.
  • Denjoy I; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (K.V.L., A. Mazzanti, I.D., T.R., C.v.d.W., A. Maltret, A.L., A.A.M.W., S.G.P.).
  • Ingles J; Molecular Cardiology, Istituti Clinici Scientifici Maugeri, Istituto di Ricovero e Cura a Carattere Scientifico and Department of Molecular Medicine, University of Pavia, Italy (A. Mazzanti, S.G.P.).
  • Till J; Cardiovascular Research Institute (E.W.T., F.H.D., N.J.R., R.C.D.), University of California, San Francisco.
  • Robyns T; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (K.V.L., A. Mazzanti, I.D., T.R., C.v.d.W., A. Maltret, A.L., A.A.M.W., S.G.P.).
  • Connors SP; Service de Cardiologie et CNMR Maladies Cardiacques Héréditaires Rares, Hôpital Bichat, Paris, France (I.D., A, Maltret, A.L.).
  • Steinberg C; Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Australia (J.I., C. Semsarian).
  • Abrams DJ; Department of Cardiology, Royal Brompton Hospital, London, United Kingdom (J.T., F.R.I.N.).
  • Pang B; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (K.V.L., A. Mazzanti, I.D., T.R., C.v.d.W., A. Maltret, A.L., A.A.M.W., S.G.P.).
  • Scheinman MM; Department of Cardiovascular Disease, University Hospitals Leuven, Belgium (T.R.).
  • Bos JM; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Memorial University, St. John's, Newfoundland and Labrador, Canada (S.P.C., S.A.D.).
  • Duffett SA; Quebec Heart and Lung Center, Laval University, Quebec City, Canada (C. Steinberg).
  • van der Werf C; Inherited Cardiac Arrhythmia Program, Boston Children's Hospital, Harvard Medical School, MA (D.J.A.).
  • Maltret A; Arrhythmia Service, University of Ottawa Heart Institute, ON, Canada (B.P., M.S.G., J.R.).
  • Green MS; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine (M.M.S., R.C.D.), University of California, San Francisco.
  • Rutberg J; Departments of Cardiovascular Medicine (Division of Heart Rhythm Services), Pediatric and Adolescent Medicine (Division of Pediatric Cardiology), and Molecular Pharmacology & Experimental Therapeutics (Windland Smith Rice Sudden Death Genomics Laboratory), Mayo Clinic, Rochester, MN (J.M.B., M.J
  • Balaji S; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Memorial University, St. John's, Newfoundland and Labrador, Canada (S.P.C., S.A.D.).
  • Cadrin-Tourigny J; Amsterdam University Medical Centre, University of Amsterdam, Heart Centre, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, The Netherlands (K.V.L., C.v.d.W., A.A.M.W.).
  • Orland KM; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (K.V.L., A. Mazzanti, I.D., T.R., C.v.d.W., A. Maltret, A.L., A.A.M.W., S.G.P.).
  • Knight LM; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (K.V.L., A. Mazzanti, I.D., T.R., C.v.d.W., A. Maltret, A.L., A.A.M.W., S.G.P.).
  • Brateng C; Service de Cardiologie et CNMR Maladies Cardiacques Héréditaires Rares, Hôpital Bichat, Paris, France (I.D., A, Maltret, A.L.).
  • Wu J; Arrhythmia Service, University of Ottawa Heart Institute, ON, Canada (B.P., M.S.G., J.R.).
  • Tang AS; Arrhythmia Service, University of Ottawa Heart Institute, ON, Canada (B.P., M.S.G., J.R.).
  • Skanes AC; Department of Pediatrics, Division of Cardiology, Oregon Health & Science University, Portland (S.B.).
  • Manlucu J; Cardiovascular Genetics Center, Montreal Heart Institute, Université de Montréal, Canada (J.C.-T.).
  • Healey JS; University of Wisconsin-Madison Inherited Arrhythmia Clinic, Division of Cardiovascular Medicine, Department of Medicine (K.M.O., C.T.J., L.L.E.), University of Wisconsin-Madison.
  • January CT; Children's Healthcare of Atlanta, Sibley Heart Center Cardiology, GA (L.M.K., P.F.).
  • Krahn AD; Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (C.B., K.K.C.).
  • Collins KK; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Western University, London, ON, Canada (K.N., J.W., A.S.T., A.C.S., J.M., J.D.R.).
  • Maginot KR; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Western University, London, ON, Canada (K.N., J.W., A.S.T., A.C.S., J.M., J.D.R.).
  • Fischbach P; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Western University, London, ON, Canada (K.N., J.W., A.S.T., A.C.S., J.M., J.D.R.).
  • Etheridge SP; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Western University, London, ON, Canada (K.N., J.W., A.S.T., A.C.S., J.M., J.D.R.).
  • Eckhardt LL; Population Health Research Institute, McMaster University, Hamilton, ON, Canada (J.S.H.).
  • Hamilton RM; University of Wisconsin-Madison Inherited Arrhythmia Clinic, Division of Cardiovascular Medicine, Department of Medicine (K.M.O., C.T.J., L.L.E.), University of Wisconsin-Madison.
  • Ackerman MJ; Cellular and Molecular Arrhythmia Research Program (C.T.J., L.L.E.), University of Wisconsin-Madison.
  • Noguer FRI; Heart Rhythm Services, Division of Cardiology, Department of Medicine (T.M.R., A.D.K.), University of British Columbia, Vancouver, Canada.
  • Semsarian C; Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (C.B., K.K.C.).
  • Jura N; Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison (K.R.M.).
  • Leenhardt A; Children's Healthcare of Atlanta, Sibley Heart Center Cardiology, GA (L.M.K., P.F.).
  • Gollob MH; Department of Pediatrics, University of Utah, and Primary Children's Hospital, Salt Lake City (S.P.E.).
  • Priori SG; University of Wisconsin-Madison Inherited Arrhythmia Clinic, Division of Cardiovascular Medicine, Department of Medicine (K.M.O., C.T.J., L.L.E.), University of Wisconsin-Madison.
  • Sanatani S; Cellular and Molecular Arrhythmia Research Program (C.T.J., L.L.E.), University of Wisconsin-Madison.
  • Wilde AAM; The Labatt Family Heart Centre (Department of Pediatrics) and Translational Medicine, The Hospital for Sick Children and the University of Toronto, ON, Canada (R.M.H.).
  • Deo RC; Departments of Cardiovascular Medicine (Division of Heart Rhythm Services), Pediatric and Adolescent Medicine (Division of Pediatric Cardiology), and Molecular Pharmacology & Experimental Therapeutics (Windland Smith Rice Sudden Death Genomics Laboratory), Mayo Clinic, Rochester, MN (J.M.B., M.J
  • Roberts JD; Department of Cardiology, Royal Brompton Hospital, London, United Kingdom (J.T., F.R.I.N.).
Circulation ; 142(10): 932-947, 2020 09 08.
Article en En | MEDLINE | ID: mdl-32693635
ABSTRACT

BACKGROUND:

Genetic variants in calsequestrin-2 (CASQ2) cause an autosomal recessive form of catecholaminergic polymorphic ventricular tachycardia (CPVT), although isolated reports have identified arrhythmic phenotypes among heterozygotes. Improved insight into the inheritance patterns, arrhythmic risks, and molecular mechanisms of CASQ2-CPVT was sought through an international multicenter collaboration.

METHODS:

Genotype-phenotype segregation in CASQ2-CPVT families was assessed, and the impact of genotype on arrhythmic risk was evaluated using Cox regression models. Putative dominant CASQ2 missense variants and the established recessive CASQ2-p.R33Q variant were evaluated using oligomerization assays and their locations mapped to a recent CASQ2 filament structure.

RESULTS:

A total of 112 individuals, including 36 CPVT probands (24 homozygotes/compound heterozygotes and 12 heterozygotes) and 76 family members possessing at least 1 presumed pathogenic CASQ2 variant, were identified. Among CASQ2 homozygotes and compound heterozygotes, clinical penetrance was 97.1% and 26 of 34 (76.5%) individuals had experienced a potentially fatal arrhythmic event with a median age of onset of 7 years (95% CI, 6-11). Fifty-one of 66 CASQ2 heterozygous family members had undergone clinical evaluation, and 17 of 51 (33.3%) met diagnostic criteria for CPVT. Relative to CASQ2 heterozygotes, CASQ2 homozygote/compound heterozygote genotype status in probands was associated with a 3.2-fold (95% CI, 1.3-8.0; P=0.013) increased hazard of a composite of cardiac syncope, aborted cardiac arrest, and sudden cardiac death, but a 38.8-fold (95% CI, 5.6-269.1; P<0.001) increased hazard in genotype-positive family members. In vitro turbidity assays revealed that p.R33Q and all 6 candidate dominant CASQ2 missense variants evaluated exhibited filamentation defects, but only p.R33Q convincingly failed to dimerize. Structural analysis revealed that 3 of these 6 putative dominant negative missense variants localized to an electronegative pocket considered critical for back-to-back binding of dimers.

CONCLUSIONS:

This international multicenter study of CASQ2-CPVT redefines its heritability and confirms that pathogenic heterozygous CASQ2 variants may manifest with a CPVT phenotype, indicating a need to clinically screen these individuals. A dominant mode of inheritance appears intrinsic to certain missense variants because of their location and function within the CASQ2 filament structure.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calsecuestrina / Taquicardia Ventricular / Mutación Missense / Heterocigoto / Homocigoto Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calsecuestrina / Taquicardia Ventricular / Mutación Missense / Heterocigoto / Homocigoto Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article